This is a phase III trial to compare the usual treatment for Locally Advanced Non-Small Cell Lung Cancer to the use of stereotactic body radiation therapy (SBRT) in addition to the usual treatment. SBRT is already commonly used in lung cancer treatment, but it has not routinely been added to the usual combination of radiation, chemotherapy, and immune therapy that doctors normally use. This study will help the study doctors find out if this different approach is better, the same, or worse than the usual approach.
If you take part in this study, you will meet frequently with a member of the study team in addition to your oncology care team. The study involves a routine blood work and diagnostic tests. Treatment will be determined by using a computer to assign you to one of the study groups. There are two group in this study. If you are assigned to group 1, you will receive the standard treatment of radiation and chemotherapy, followed by immune therapy. If you are assigned to group 2, you will receive SBRT for about 1-2 weeks before starting the standard treatment of radiation and chemotherapy, followed by immune therapy. You will also be asked to fill out some surveys about your physical and emotional well-being and your symptoms.
Ashley Weiner
Lineberger Comprehensive Cancer Center
Clinical or Medical
Interventional
Cancer (Lung)
23-1739
Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.
Questions?
